All In Biotech

NDA 204063 · Biogen

Tecfidera

Dimethyl Fumarate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Mar 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Mar 27, 2013

Approved uses

4

Original approval plus efficacy supplements

Registered trials

236

49 Phase 3, 19 recruiting

FAERS reports

122,568

40,867 serious, 2,171 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 4, 2025.

TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Mechanism: The mechanism by which dimethyl fumarate (DMF) exerts its therapeutic effect in multiple sclerosis is unknown. DMF and the metabolite, monomethyl fumarate (MMF), have been shown to activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • TECFIDERA · DIMETHYL FUMARATE 120MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription · TE AB
  • TECFIDERA · DIMETHYL FUMARATE 240MG · CAPSULE, DELAYED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Dimethyl" as an intervention, any sponsor and status, largest first.

All 236 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • flushing17,125
  • nausea8,981
  • diarrhoea8,302
  • multiple sclerosis relapse8,147
  • fatigue6,970
  • multiple sclerosis5,766
  • vomiting5,659
  • memory impairment5,573
  • gastric disorder5,551
  • abdominal pain upper5,420
  • drug ineffective5,238
  • pruritus5,080

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20081
20091
20101
20115
201214
201314,596
201418,283
201512,884
201613,524
201712,338
201812,142
201910,538
20209,477
20216,132
20225,229
20233,259
20241,755
20251,526
2026863

Recalls

1 FDA enforcement reports for this application.

  • Jun 23, 2020 · Class III · Terminated

    cGMP deviations: one lot of the product was distributed to US Markets despite being rejected during in-process control.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tecfidera (Dimethyl Fumarate)

2024 spending

$163M

Beneficiaries

2,117

16,641 claims

Per beneficiary

$76,921

$149.87 per unit

View as table
YearSpending
2020$1,054,984,601
2021$569,199,653
2022$343,225,607
2023$234,518,996
2024$162,842,335

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 730 on PubMed

Sponsor: Biogen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.